TRMT6‐Mediated m 1 A Modification of CDK9 mRNA is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma
Advanced Science · 2026-07 · 13 (39)
DOI: 10.1002/advs.202514172 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.04.2026. Verfasst von Rui Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cyclin-Dependent Kinase 9, RNA, Messenger. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shaanxi Provincial Key Research and Development Program.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of death worldwide, with hepatitis B virus (HBV) infection being the major risk factor. Dysregulation of mRNA methylation contributes to tumorigenesis and virus replication. However, the association of N 1 ‐methyladenosine (m 1 A) modification with HCC progression and HBV replication remains unclear. Here, single‐nucleus RNA sequencing (snRNA‐seq) of 4 HCC and 7 adjacent tissues (2 from this study and 5 from the GSE242889) revealed elevated mRNA methylation in HCCs, with increased expression of m 1 A “writers” and “readers” and decreased expression of m 1 A “erasers”. Among them, m 1 A writer TRMT6 was up‐regulated in HCC and correlated with poor patient prognosis. TRMT6 knockdown strikingly restrained the malignant phenotypes and tumorigenicity of HCC cells as well as HBV replication. Mechanistically, TRMT6‐mediated m 1 A modification enhanced the stability and translation efficiency of cyclin‐dependent kinase 9 ( CDK9 ) mRNA. Elevated CDK9 facilitated HCC progression by up‐regulating its downstream oncogenic effectors, and stimulated HBV replication via TARDBP phosphorylation at Ser254 to enhance pgRNA transcription and repress pgRNA splicing. CDK9 inhibitor FIT‐039 abrogated these effects without obvious toxicity. Thus, TRMT6‐mediated m 1 A modification dually drives HCC malignancy and HBV replication, representing a promising therapeutic target, and CDK9 inhibition may constitute an effective strategy for HBV‐related HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. China.
- International Joint Research Center for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. China.
- Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, P.R. China.
- Yulin Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Yulin, P. R. China.
- Department of Radio-Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. China.
- Department of Stomatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. China.
ORCID-Profile: Peng Hou
Förderung
- National Natural Science Foundation of China
- Shaanxi Provincial Key Research and Development Program
Zitieren
APA
Zhang, R., Zong, D., Liu, R., Wang, Y., Gu, Q., Yao, Y., Zheng, W., Yuan, M., Wang, S., Cui, R., Li, D., Dang, S., & Hou, P. (2026). TRMT6‐Mediated m 1 A Modification of CDK9 mRNA is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma. Advanced Science, 13(39). https://doi.org/10.1002/advs.202514172
Vancouver
Zhang R, Zong D, Liu R, Wang Y, Gu Q, Yao Y, et al. TRMT6‐Mediated m 1 A Modification of CDK9 mRNA is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma. Advanced Science. 2026;13(39). doi:10.1002/advs.202514172
BibTeX
@article{Zhang2026,
author = {Zhang, Rui and Zong, Dandan and Liu, Rui and Wang, Yubo and Gu, Qingqing and Yao, Yao and Zheng, Wenfang and Yuan, Mengmeng and Wang, Simeng and Cui, Rongrong and Li, Daxu and Dang, Siwen and Hou, Peng},
title = {TRMT6‐Mediated m 1 A Modification of CDK9 mRNA is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {39},
doi = {10.1002/advs.202514172}
}
EUVIMED